Redx 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   4 Trials   35 News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zamaporvint (RXC004) / Redx
ACTRN12624000588594: Clinical study assessing the preliminary efficacy and safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care

Not yet recruiting
2
20
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic Cancer
 
 
PORCUPINE, NCT04907539 / 2020-003132-24: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Completed
2
25
Europe, US, RoW
RXC004, Nivolumab, Denosumab
Redx Pharma Plc
Colorectal Cancer
04/24
04/24
KEYNOTE-E86, NCT04907851: A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Completed
2
45
Europe, RoW
RXC004, zamaporvint, Denosumab, pembrolizumab, KEYTRUDA®
Redx Pharma Plc, Merck Sharp & Dohme LLC
Advanced Solid Tumours
11/23
11/23
NCT03447470 / 2017-000720-98: Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Completed
1
46
Europe
RXC004, Nivolumab
Redx Pharma Ltd
Cancer, Solid Tumor
09/23
09/23
JZP815 / Jazz
NCT05557045: A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Recruiting
1
332
US
JZP815
Jazz Pharmaceuticals
Advanced Cancer, Metastatic Cancer, Solid Tumor
04/28
04/28
zelasudil (RXC007) / Redx
2022-000498-15: A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with IPF. Uno studio per studiare la sicurezza, la tollerabilità e il potenziale effetto di RXC007 nei pazienti con IPF.

Not yet recruiting
2
64
Europe, RoW
RXC007 20 mg Capsule, RXC007 50 mg Capsule, [NA], Capsule, hard
Redx Pharma plc, Redx Pharma Plc, Redx Pharma Plc, Redx Pharma PLC
Idiopathic Pulmonary Fibrosis (IPF) Fibrosi polmonare idiopatica (IPF), Lung condition associated with fibrosis and inflammation Condizione polmonare associata a fibrosi e infiammazione, Body processes [G] - Physiological processes [G07]
 
 
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF
Active, not recruiting
2
48
Europe, RoW
RXC007, Placebo
Redx Pharma Plc, Simbec-Orion Group
IPF, Fibrosis
06/24
01/25
NCT04931147: A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Completed
1
90
Europe
RXC007, RXC007 Matching Placebo
Redx Pharma Plc, Simbec Research
Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis, Liver Diseases, Kidney Diseases
03/23
03/23
AZD5055 / AstraZeneca
NCT05630677: A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Hourglass Feb 2023 - Jun 2023 : Data from trial for healthy volunteers
Completed
1
21
US
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
AstraZeneca, Parexel
Healthy Volunteers
02/23
02/23
NCT05134727: Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Hourglass Feb 2023 - Jun 2023 : Data from trial for healthy volunteers
Completed
1
63
US
AZD5055, Placebo
AstraZeneca
Idiopathic Pulmonary Fibrosis
03/23
03/23
NCT05644600: A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Terminated
1
18
Europe
Nintedanib, AZD5055
AstraZeneca, Parexel
Healthy Subjects
07/23
07/23
NCT05955183: Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

Completed
1
38
US
AZD5055, Placebo
AstraZeneca
Healthy Participants
12/23
12/23
REDX05358 / Jazz
No trials found
REDX08087 / Redx
No trials found
RXC008 / Redx
No trials found
MAPK pathway therapeutic / Jazz, Redx
No trials found

Download Options